Literature DB >> 6893937

Congenital methaemoglobinaemia due to NADH methaemoglobin reductase deficiency: successful treatment with oral riboflavin.

M Hirano, T Matsuki, K Tanishima, M Takeshita, S Shimizu, Y Nagamura, Y Yoneyama.   

Abstract

A Japanese family with congenital methaemoglobinaemia is described. The family pedigree was compatible with autosomal recessive type of inheritance. The increased methaemoglobin concentration was ascribed to the red cell NADH diaphorase deficiency associated with the almost complete lack of one of the two peaks of the diaphorase activity as separated by DEAE Sephadex column chromatography. The NADH diaphorase and NADH methaemoglobin reductase deficiency was limited to the red cells. The methaemoglobin content in the blood of the propositus was 17.8% and isoelectric focusing analysis on a polyacrylamide gel plate showed that the haemoglobin consisted of 65.2% oxyhaemoglobin (alpha 2+ beta 2+)2, 29.6% half-oxidized forms, 20.9% (alpha 3+ beta 2+)2 and 8.7% (alpha 2+ beta 3+)2, and 3% full-oxidized methaemoglobin (alpha 3+ beta 3+)2. Oral administration of riboflavin 120 mg/d resulted in a gradual but significant decrease in the level of the met-form haemoglobins in parallel with a gradual increase in the red cell flavin content. Riboflavin is considered to be effective by activating the NADPH diaphorase (NADPH flavin reductase) system and appears to be useful for the treatment of congenital methaemoglobinaemia.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6893937     DOI: 10.1111/j.1365-2141.1981.tb02802.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Characterization of NADPH-dependent methemoglobin reductase as a heme-binding protein present in erythrocytes and liver.

Authors:  F Xu; K S Quandt; D E Hultquist
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  In vitro activity of riboflavin against the human malaria parasite Plasmodium falciparum.

Authors:  T Akompong; N Ghori; K Haldar
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

3.  Gametocytocidal activity and synergistic interactions of riboflavin with standard antimalarial drugs against growth of Plasmodium falciparum in vitro.

Authors:  T Akompong; S Eksi; K Williamson; K Haldar
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

Review 4.  Recommendations for diagnosis and treatment of methemoglobinemia.

Authors:  Achille Iolascon; Paola Bianchi; Immacolata Andolfo; Roberta Russo; Wilma Barcellini; Elisa Fermo; Gergely Toldi; Stefano Ghirardello; Davis Rees; Richard Van Wijk; Antonis Kattamis; Patrick G Gallagher; Noemi Roy; Ali Taher; Razan Mohty; Andreas Kulozik; Lucia De Franceschi; Antonella Gambale; Mariane De Montalembert; Gian Luca Forni; Cornelis L Harteveld; Josef Prchal
Journal:  Am J Hematol       Date:  2021-09-23       Impact factor: 13.265

5.  A Case of Congenital Methemoglobinemia: Rare but Real.

Authors:  Sanjay Paudel; Nirajan Adhikari; Shobha Mandal; Panit Srivatana
Journal:  Cureus       Date:  2022-04-15

Review 6.  Dental anesthesia management of methemoglobinemia-susceptible patients: a case report and review of literature.

Authors:  David L Hall; Megann K Moses; Joel M Weaver; Jason P Yanich; James W Voyles; Daniel N Reed
Journal:  Anesth Prog       Date:  2004

7.  A rare cause of cyanosis: Congenital methemoglobinemia.

Authors:  Rahma Guedri; Nada Missaoui; Leila Essaddam; Saayda Ben Becher
Journal:  Clin Case Rep       Date:  2021-07-10

8.  Long-term Treatment with Methylene Blue in a Dog with Hereditary Methemoglobinemia Caused by Cytochrome b5 Reductase Deficiency.

Authors:  J A Jaffey; M R Harmon; N A Villani; E K Creighton; G S Johnson; U Giger; J R Dodam
Journal:  J Vet Intern Med       Date:  2017-09-29       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.